Compare CDW Corp. (CDW) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Illumina, Inc. — how do they compare? CDW Corp. trades at $144.5 (market cap $17.81B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Illumina, Inc. is the larger of the two by market cap, and CDW Corp. pays a 1.81% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| CDW | ILMN | |
|---|---|---|
Market Cap | $17.81B | $28.93B |
Sector | Technology | Health |
52-Week High | $182.18 | $194.33 |
52-Week Low | $99.30 | $91.00 |
Enterprise Value | $23.02B | $30.32B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $144.36, down slightly by 0.02% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $145.83. The company reported Q1 2026 earnings that met expectations with $2.28 EPS, following beats in previous quarters. Revenue for 2025 was $22.42B with a net income margin of 4.7%, while valuation metrics show a P/E of 17.58 and P/S of 0.83. Recent news highlights AI infrastructure demand and a $1B share repurchase authorization.
The outlook for CDW is positive, driven by AI growth opportunities and strong profitability, but risks include margin pressure and competitive threats. Analysts are bullish with 70.59% buy ratings, suggesting potential upside from current levels, though investors should monitor execution on earnings targets and macroeconomic conditions.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
